Joint Tsinghua-Liverpool Research Team Discover New Charge Storage Mechanism
16.8.2021 12:00:00 EEST | Business Wire | Press release
Due to their high energy density and low cost, metal-air batteries are one of the most promising power sources of the future. A joint Tsinghua-Liverpool research team has recently developed a new charge storage mechanism that allows rechargeability within calcium-air batteries - a major step forward in battery technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210816005031/en/
Lu in Prof Hu’s lab where he set up experiments to cross compare results obtained at NTHU and at UoL.(Photo: National Tsing Hua University)
This discovery has been published in Chemical Science. The lead author of the paper, Yi-Ting Lu, is a joint doctoral student at Tsinghua and Liverpool, whose supervisors are Prof. Chi-Chang Hu (Department of Chemical Engineering, NTHU) and Prof. Laurence Hardwick (Department of Chemistry, UoL).
A major breakthrough related to Ca-air batteries
Prof. Hu said conventional lithium-ion batteries have a limited practical capacity. Thereby many researchers are working on developing alternative battery technologies. Their focus is on metal-air batteries based on zinc, lithium, sodium, potassium, calcium, magnesium, and aluminum. The advantage of the calcium-air battery is its high specific energy—five times that of traditional lithium-ion batteries. However, the feasibility of calcium-air batteries remains hampered by one major drawback—it cannot be recharged.
Lu explained that metal-air batteries are electrochemical cells usually using an active metal as the negative electrode, and a porous carbon material in contact with the air as the positive electrode. When the metal oxidized the oxygen at the positive electrode is reduced, generating electric current.
After completing his first year of doctoral studies at NTHU, Lu enrolled at the Stephenson Institute for Renewable Energy at UoL in September 2018. Under the supervision of Prof. Hardwick, he began doing research on the electrolyte used in calcium-air batteries.
Lu found when a single electrode is repeatedly charged and discharged, initially no reversibility can be observed, but after a few dozen cycles it gradually displays some reversibility. Surprisingly, the result seemed completely different from those in literature. The research team conducted a series of experiments aimed at uncovering the mechanism behind this phenomenon. On the electrode surface, the discharge products form a calcium oxide (CaxOy) interlayer, where the discharge product of oxygen, known as superoxide, is confined, allowing the superoxide to be then readily oxidized. This suggests the oxygen could probably be repeatedly oxidized/reduced, so that the cell can be continuously discharged/recharged.
Dr. Alex Neale, a Liverpool postdoctoral researcher, who is also part of the research team, said that through systematic electrochemical and spectroscopy investigations, the team began to understand the origins of this charge storage mechanism that facilitates a previously unseen degree of reversibility for systems based on the calcium-air battery.
Prof. Hardwick said the team will focus on designing new battery systems that use this newly discovered charge storage mechanism. He added that it was the cooperative research that made their discovery possible, and there are plans for even closer cooperation between NTHU and UoL in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005031/en/
Contact information
Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
